EXICURE
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNAâ„¢) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
EXICURE
Industry:
Biotechnology Genetics Life Science Therapeutics
Founded:
2009-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Website Url:
http://www.exicuretx.com
Total Employee:
11+
Status:
Active
Contact:
(847)673-1700
Total Funding:
105.45 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Font Awesome
Similar Organizations
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Luye Pharma
Luye Pharma investment in Venture Round - Exicure
HT Capital
HT Capital investment in Venture Round - Exicure
Alumni Ventures
Alumni Ventures investment in Venture Round - Exicure
Knoll Capital Management
Knoll Capital Management investment in Venture Round - Exicure
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Venture Round - Exicure
Katalyst Securities
Katalyst Securities investment in Venture Round - Exicure
David R. Walt
David R. Walt investment in Venture Round - Exicure
Tempus
Tempus investment in Venture Round - Exicure
Craig Mundie
Craig Mundie investment in Venture Round - Exicure
Mark Tompkins
Mark Tompkins investment in Venture Round - Exicure
Official Site Inspections
http://www.exicuretx.com Semrush global rank: 4.31 M Semrush visits lastest month: 2.66 K
- Host name: 115.147.96.66.static.eigbox.net
- IP address: 66.96.147.115
- Location: Burlington United States
- Latitude: 42.509
- Longitude: -71.1984
- Metro Code: 506
- Timezone: America/New_York
- Postal: 01803